You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

NPC1L1 transporter

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Pancreas Cancer Trial in Quebec city (Cholesterol metabolism disruption)

Recruiting
  • Pancreatic Ductal Adenocarcinoma
  • +3 more
  • Cholesterol metabolism disruption
  • Quebec city, Quebec, Canada
    CHU de Québec-Université Laval
Oct 17, 2022

Liver Cirrhosis Trial (Rosuvastatin, Digoxin, Metformin hydrochlorid)

Not yet recruiting
  • Liver Cirrhosis
  • (no location specified)
Feb 27, 2023

Healthy Participants Trial in Salt Lake City (DC-806, Midazolam, Repaglinide)

Not yet recruiting
  • Healthy Participants
  • Salt Lake City, Utah
    ICON Phase 1 Clinic
Oct 16, 2023

NPC Trial in Guangzhou (Sintilimab, IBI310)

Active, not recruiting
  • NPC
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 3, 2022

Sickle Cell Disease Trial in San Antonio (Voxelotor, Bupropion, Repaglinide)

Recruiting
  • Sickle Cell Disease
  • San Antonio, Texas
    ICON Early Phase Services, LLC
Jul 31, 2023

Nasopharyngeal Carcinoma Trial in Guangzhou (BL-B01D1, capecitabine, gemcitabine)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 31, 2023

Nasopharyngeal Carcinoma Trial in Guangzhou (Dalpiciclib Isetionate Tablets, Camrelizumab)

Recruiting
  • Nasopharyngeal Carcinoma
  • Dalpiciclib Isetionate Tablets, Camrelizumab
  • Guangzhou, Guangdong, China
    Department of Nasopharyngeal Carcinoma, Sun Yat-sen University C
Feb 2, 2023

GLUT1 Deficiency Syndrome, Glucose Transporter Type 1 Deficiency Syndrome, Glucose Transporter type1 (GLUT-1) Deficiency Trial

Recruiting
  • GLUT1 Deficiency Syndrome
  • +3 more
  • No intervention
  • Dallas, Texas
    UT Southwestern Medical Center
Feb 1, 2022

Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS) Trial (Triheptanoin)

Available
  • Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)
  • (no location specified)
Nov 22, 2022

Epilepsy, GLUT1DS1, Glut1 Deficiency Syndrome 1, Autosomal Recessive Trial in Dallas (Triheptanoin)

Active, not recruiting
  • Epilepsy
  • +6 more
  • Dallas, Texas
    UT Southwestern Medical Center
Feb 1, 2022

Kidney Transplant Recipients Trial in Toronto (Dapagliflozin 10 MG, Semaglutide, 1.0 mg/mL)

Not yet recruiting
  • Kidney Transplant Recipients
  • Dapagliflozin 10 MG
  • Semaglutide, 1.0 mg/mL
  • Toronto, Ontario, Canada
    Toronto General Hospital
Jul 6, 2023

Nasopharyngeal Carcinoma Trial in Shanghai (Anti-EGFR and PD-1 inhibitor arm)

Recruiting
  • Nasopharyngeal Carcinoma
  • Anti-EGFR and PD-1 inhibitor arm
  • Shanghai, Shanghai, China
    Eye & ENT Hospital of Fudan University
Nov 26, 2023

Nasopharyngeal Carcinoma, Intensity-Modulated Radiotherapy Trial in Zhongshan (Reduction CTVp1, Non-reduction CTVp1)

Recruiting
  • Nasopharyngeal Carcinoma
  • Intensity-Modulated Radiotherapy
  • Reduction CTVp1
  • Non-reduction CTVp1
  • Zhongshan, Guangdong, China
    Zhongshan City People's Hospital
Aug 8, 2023

Brain Metabolism Observed at 7 Tesla

Recruiting
  • Glut1 Deficiency Syndrome 1
  • +6 more
  • Magnetic resonance imaging
  • Dallas, Texas
    UT Southwestern Medical Center
Aug 24, 2022

Nasopharyngeal Carcinoma Trial in Guangzhou (Apatinib, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel),

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • Apatinib, Camrelizumab, Chemotherapy (gemcitabine/ capecitabine/ docetaxel)
  • +3 more
  • Guangzhou, Guangdong, China
    Department of Nasopharyngeal Carcinoma, Sun Yat-sen University C
Sep 17, 2022

Locally Advanced Nasopharyngeal Carcinoma, Envafolimab, Induction Chemo Trial in Guangzhou (Envafolimab Plus Chemoradiotherapy)

Recruiting
  • Locally Advanced Nasopharyngeal Carcinoma
  • +3 more
  • Envafolimab Plus Chemoradiotherapy
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Aug 9, 2022

Safety and Pharmacokinetics Trial in Shinjuku-Ku (NPC-22, NPC-22 Placebo)

Completed
  • Safety and Pharmacokinetics
  • Shinjuku-Ku, Tokyo, Japan
    Medical Corporation Shinanokai Shinanozaka Clinic
Feb 4, 2022

GLUT1DS1, Epilepsy, Glut1 Deficiency Syndrome 1, Autosomal Recessive Trial in Dallas (Triheptanoin)

Active, not recruiting
  • GLUT1DS1
  • +6 more
  • Dallas, Texas
    University of Texas Southwestern Medical Center
Jul 30, 2021

Rheumatoid Arthritis Trial in Saint Paul (Atorvastatin, Pravastatin, Rosuvastatin)

Completed
Has Results
  • Rheumatoid Arthritis
  • Saint Paul, Minnesota
    Prism Research, LLC
May 26, 2022

PD-1 Inhibitor, G-CSF Trial in Guangzhou (Camrelizumab, G-CSF)

Recruiting
  • PD-1 Inhibitor
  • G-CSF
  • Guangzhou, Guangdong, China
    Department of Nasopharyngeal Carcinoma, Sun Yat-sen University C
Feb 2, 2022

Glut1 Deficiency Syndrome Trial in Paris (GLUT1 DS)

Completed
  • Glut1 Deficiency Syndrome
  • GLUT1 DS
  • Paris, France
    Brain and Spine Institute
Aug 24, 2021

Essential Hypertension Trial in Seoul (L04RD1, L04TD3)

Completed
  • Essential Hypertension
  • Seoul, Korea, Republic of
    H plus Yangji Hospital
Aug 7, 2023

Healthy Trial in Seoul (L04RD1, L04TD1)

Completed
  • Healthy
  • Seoul, Korea, Republic of
    H plus Yangji Hospital
Jan 10, 2023

Lung Cancer Trial (Centipeda minima+PD-1/PD-L1 inhibitor, PD-1/PD-L1 inhibitor)

Not yet recruiting
  • Lung Cancer
  • Centipeda minima+PD-1/PD-L1 inhibitor
  • PD-1/PD-L1 inhibitor
  • (no location specified)
Feb 17, 2023

Glioblastoma Trial (Bevacizumab, PD-L1 t-haNK, N-803)

Not yet recruiting
  • Glioblastoma
  • (no location specified)
Sep 25, 2023